贝达药业(300558.SZ)：公司团队正加紧准备恩沙替尼申报材料 尽快递交新增适应症的NDA申请

Core Viewpoint - Betta Pharmaceuticals (300558.SZ) has reported positive interim data analysis from clinical trials of Ensartinib for postoperative adjuvant treatment of ALK-positive NSCLC, achieving the predefined primary research endpoint [1] Group 1 - The company is accelerating the preparation of submission materials for the new indication [1] - The company plans to submit a New Drug Application (NDA) as soon as possible [1]